These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 23387326)
1. Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD. Teixeira AC; Saraiva MJ J Cell Mol Med; 2013 Mar; 17(3):429-35. PubMed ID: 23387326 [TBL] [Abstract][Full Text] [Related]
2. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy. Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615 [TBL] [Abstract][Full Text] [Related]
3. Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy. Palha JA; Moreira P; Olofsson A; Lundgren E; Saraiva MJ J Mol Med (Berl); 2001; 78(12):703-7. PubMed ID: 11434723 [TBL] [Abstract][Full Text] [Related]
5. Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo. Wei L; Kawano H; Fu X; Cui D; Ito S; Yamamura K; Ishihara T; Tokuda T; Higuchi K; Maeda S Amyloid; 2004 Jun; 11(2):113-20. PubMed ID: 15478467 [TBL] [Abstract][Full Text] [Related]
6. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Gonçalves P; Martins H; Costelha S; Maia LF; Saraiva MJ Amyloid; 2016 Dec; 23(4):249-253. PubMed ID: 27884058 [TBL] [Abstract][Full Text] [Related]
7. Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Terazaki H; Ando Y; Fernandes R; Yamamura K; Maeda S; Saraiva MJ Lab Invest; 2006 Jan; 86(1):23-31. PubMed ID: 16357867 [TBL] [Abstract][Full Text] [Related]
8. SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Ueda M; Misumi Y; Mizuguchi M; Nakamura M; Yamashita T; Sekijima Y; Ota K; Shinriki S; Jono H; Ikeda S; Suhr OB; Ando Y Clin Chem; 2009 Jun; 55(6):1223-7. PubMed ID: 19372189 [TBL] [Abstract][Full Text] [Related]
9. Serum transthyretin levels in Swedish TTR V30M carriers. Buxbaum J; Anan I; Suhr O Amyloid; 2010 Jun; 17(2):83-5. PubMed ID: 20462367 [TBL] [Abstract][Full Text] [Related]
10. Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model. Batista AR; Sena-Esteves M; Saraiva MJ Biochim Biophys Acta; 2013 Aug; 1832(8):1183-93. PubMed ID: 23579071 [TBL] [Abstract][Full Text] [Related]
12. Antibody therapy for familial amyloidotic polyneuropathy. Su Y; Jono H; Torikai M; Hosoi A; Soejima K; Guo J; Tasaki M; Misumi Y; Ueda M; Shinriki S; Shono M; Obayashi K; Nakashima T; Sugawara K; Ando Y Amyloid; 2012 Jun; 19 Suppl 1():45-6. PubMed ID: 22506915 [TBL] [Abstract][Full Text] [Related]
13. The inflammatory response to sciatic nerve injury in a familial amyloidotic polyneuropathy mouse model. Gonçalves NP; Teixeira-Coelho M; Saraiva MJ Exp Neurol; 2014 Jul; 257():76-87. PubMed ID: 24800914 [TBL] [Abstract][Full Text] [Related]
14. Electrophysiological parameters that contribute to the pathogenesis of familial amyloid polyneuropathy caused by transthyretin mutations. Lai HJ; Lai WT; Jin L; Kuo KT; Lee MJ J Neurol Sci; 2020 Jun; 413():116810. PubMed ID: 32247966 [TBL] [Abstract][Full Text] [Related]
15. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine. Obayashi K; Tasaki M; Jono H; Ueda M; Shinriki S; Misumi Y; Yamashita T; Oshima T; Nakamura T; Ikemizu S; Anan I; Suhr O; Ando Y Clin Chim Acta; 2013 Apr; 419():127-31. PubMed ID: 23462670 [TBL] [Abstract][Full Text] [Related]
16. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy. Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783 [TBL] [Abstract][Full Text] [Related]
17. A transgenic rat with the human ATTR V30M: a novel tool for analyses of ATTR metabolisms. Ueda M; Ando Y; Hakamata Y; Nakamura M; Yamashita T; Obayashi K; Himeno S; Inoue S; Sato Y; Kaneko T; Takamune N; Misumi S; Shoji S; Uchino M; Kobayashi E Biochem Biophys Res Commun; 2007 Jan; 352(2):299-304. PubMed ID: 17126291 [TBL] [Abstract][Full Text] [Related]
18. Gene therapy approach to FAP: in vivo influence of T119M in TTR deposition in a transgenic V30M mouse model. Batista AR; Gianni D; Ventosa M; Coelho AV; Almeida MR; Sena-Esteves M; Saraiva MJ Gene Ther; 2014 Dec; 21(12):1041-50. PubMed ID: 25273354 [TBL] [Abstract][Full Text] [Related]
19. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367 [TBL] [Abstract][Full Text] [Related]